Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Atrial fibrillation

Apixaban safer than warfarin for patients regardless of stroke history

A secondary analysis of the AUGUSTUS trial has suggested that apixaban offers more favourable outcomes than warfarin for patients requiring an anticoagulant, regardless of a patient’s stroke history.

Apixaban anticoagulant drug

Source: Dr P Marazzi / Science Photo Library 

Researchers found that patients with atrial fibrillation experienced less bleeding and fewer events if they received apixaban than if they received a vitamin K antagonist

Apixaban is associated with less major bleeding, death and hospitalisation than vitamin K antagonist warfarin, regardless of a patient’s stroke history, a secondary analysis of the AUGUSTUS trial, which was previously published in the New England Journal of Medicine (18 March 2019), has indicated[1],[2].

For the secondary analysis, presented at the American Stroke Association’s International Stroke Conference 2020 (21 February 2020) in Los Angeles, California, trial investigators divided the AUGUSTUS study population into two groups: patients with and without a history of stroke, transient ischemic attack (TIA) or thromboembolism. Of the 4,581 patients with the information available, 13.8% had experienced a stroke, TIA or thromboembolism.

Results were consistent with the trial’s main finding — that patients with atrial fibrillation and an acute coronary syndrome, or undergoing percutaneous coronary intervention with a P2Y12 inhibitor (such as clopidogrel), experienced less major bleeding and fewer events if they received apixaban than if they received a vitamin K antagonist. This was irrespective of whether they had experienced a stroke in the past. The risk of bleeding was higher with aspirin than placebo among patients with no prior events.

“Even in a high-risk group of patients with prior stroke, ‘less is more’,” said Maria Cecilia Bahit, lead investigator and chief of cardiology at INECO Neurociencias, Rosario, Argentina.

“A strategy of apixaban plus a P2Y12 inhibitor without aspirin has the most favourable outcomes, and triple therapy — a vitamin K antagonist plus aspirin, plus a P2Y12 inhibitor — should be avoided.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207814

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.